LFCR — Lifecore Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- $236.22m
- $355.74m
- $128.26m
- 52
- 36
- 97
- 65
Annual cashflow statement for Lifecore Biomedical, fiscal year end - May 26th, USD millions except per share, conversion factor applied.
2020 May 31st | C2021 May 30th | C2022 May 29th | 2023 May 28th | 2024 May 26th | |
|---|---|---|---|---|---|
| Period Length: | 53 W | 52 W | 52 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -38.2 | -32.3 | -117 | -99.6 | 12 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 35.4 | 27 | 86 | 48.5 | -17.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -27.7 | 9.76 | -3.1 | 20 | -3.85 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -17 | 16.5 | -22.6 | -17.4 | -0.217 |
| Capital Expenditures | -26.7 | -25.2 | -29.9 | -21.5 | -17.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 2.8 | 12.9 | 110 | 16.7 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -23.9 | -12.3 | 80 | -4.81 | -17.9 |
| Financing Cash Flow Items | -1.79 | -10.9 | -1.61 | -6.32 | 4.62 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 40 | -3.42 | -57 | 39.7 | 7.51 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.912 | 0.742 | 0.348 | 17.4 | -10.6 |